Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Green Scientific Labs Holdings Inc. operates within the healthcare sector, focusing on the development and manufacturing of specialty pharmaceuticals and generic drugs. The company has a competitive edge through its proprietary formulations and a robust pipeline of products aimed at addressing unmet medical needs, particularly in the Canadian market.
GSL generates revenue primarily through the sale of specialty pharmaceuticals and generic drugs. The company leverages its proprietary formulations to command higher pricing power in niche markets, while also competing on cost for generic products. Its focus on R&D allows for a steady pipeline of new products, which can enhance margins.
FDA approvals for new drugs
Changes in healthcare regulations affecting drug pricing
Market entry of new competitors
Partnerships with larger pharmaceutical companies
Regulatory changes that could impact drug pricing and approval processes
Technological disruption in drug development processes
Increased competition from generic drug manufacturers
Potential entry of large pharmaceutical companies into niche markets
High operating losses leading to liquidity issues
Negative equity position due to accumulated losses
moderate - The healthcare sector tends to be less sensitive to economic cycles, but demand for specialty drugs can fluctuate with consumer spending.
Higher interest rates could increase the cost of financing for GSL, impacting its ability to invest in R&D and expand operations. Additionally, rising rates may dampen consumer spending on healthcare.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the pharmaceutical sector.
high - The stock has shown significant volatility, with a 450% return over the last three months.